Literature DB >> 21814034

DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells.

Moriya Iwaizumi1, Stephanie Tseng-Rogenski, John M Carethers.   

Abstract

BACKGROUND: 5-fluorouracil (5FU)-based chemotherapy is the standard treatment for advanced stage colorectal cancer (CRC) patients. Several groups including ours have reported that stage II-III colorectal cancer patients whose tumors retain DNA Mismatch repair (MMR) function derive a benefit from 5FU, but patients with tumors that lost MMR function do not. Although MMR recognition of 5FU incorporated in DNA has been demonstrated biochemically, it has not been demonstrated within cells to execute 5FU cytotoxicity. AIM: To establish an efficient construction model for 5FU within DNA and demonstrate that 5FU incorporated into DNA can trigger cellular cytotoxicity executed by the DNA MMR system.
METHODS: We constructed a 5FdU-containing heteroduplex plasmid (5FdU plasmid) and 5FdU-containing linear dsDNA (5FdU linear DNA), and transfected these into MMR-proficient, hMLH1-/- and hMSH6-/- cells. We observed cell growth characteristics of both transfectants for 5FU-induced cytotoxicity.
RESULTS: MMR- proficient cells transfected with the 5FdU plasmid but not the 5FdU linear DNA showed reduced cell proliferation by MTS and clonogenic assays, and demonstrated cell morphological change consistent with apoptosis. In MMR-deficient cells, neither the 5FdU plasmid nor 5FdU linear DNA induced cell growth or morphological changes different from controls.
CONCLUSION: 5FdU as heteroduplex DNA in plasmid but not linear form triggered cytotoxicity in a MMR-dependent manner. Thus 5FU incorporated into DNA, separated from its effects on RNA, can be recognized by DNA MMR to trigger cell death.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21814034      PMCID: PMC3367669          DOI: 10.4161/cbt.12.8.17169

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  33 in total

1.  Measurement of DNA mismatch repair activity in live cells.

Authors:  Xiufen Lei; Yong Zhu; Alan Tomkinson; LuZhe Sun
Journal:  Nucleic Acids Res       Date:  2004-07-12       Impact factor: 16.971

2.  Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines.

Authors:  J Holmes; S Clark; P Modrich
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

3.  Chemical consequences of incorporation of 5-fluorouracil into DNA as studied by NMR.

Authors:  A B Kremer; T Mikita; G P Beardsley
Journal:  Biochemistry       Date:  1987-01-27       Impact factor: 3.162

Review 4.  Mismatch repair in replication fidelity, genetic recombination, and cancer biology.

Authors:  P Modrich; R Lahue
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

5.  Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility.

Authors:  Guohze Yang; Stefan J Scherer; Scarlet S Shell; Kan Yang; Mimi Kim; Martin Lipkin; Raju Kucherlapati; Richard D Kolodner; Winfried Edelmann
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

6.  Equilibrium between a wobble and ionized base pair formed between fluorouracil and guanine in DNA as studied by proton and fluorine NMR.

Authors:  L C Sowers; R Eritja; B Kaplan; M F Goodman; G V Fazakerly
Journal:  J Biol Chem       Date:  1988-10-15       Impact factor: 5.157

7.  Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.

Authors:  J A Laurie; C G Moertel; T R Fleming; H S Wieand; J E Leigh; J Rubin; G W McCormack; J B Gerstner; J E Krook; J Malliard
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

8.  Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick; M H Veeder; J A Mailliard
Journal:  Ann Intern Med       Date:  1995-03-01       Impact factor: 25.391

9.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

10.  Heteroduplex repair in extracts of human HeLa cells.

Authors:  D C Thomas; J D Roberts; T A Kunkel
Journal:  J Biol Chem       Date:  1991-02-25       Impact factor: 5.157

View more
  28 in total

1.  GRG Profiles: John M. Carethers.

Authors:  John M Carethers
Journal:  Dig Dis Sci       Date:  2016-06       Impact factor: 3.199

2.  An active molecule from Pulsatilla chinensis, Pulsatilla saponin A, induces apoptosis and inhibits tumor growth of human colon cancer cells without or with 5-FU.

Authors:  Liming Xu; Guilian Cheng; Yi Lu; Shaofeng Wang
Journal:  Oncol Lett       Date:  2017-03-21       Impact factor: 2.967

3.  Comparative label-free LC-MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5-fluorouracil.

Authors:  Kerry M Bauer; Paul A Lambert; Amanda B Hummon
Journal:  Proteomics       Date:  2012-06       Impact factor: 3.984

4.  HEREDITARY, SPORADIC AND METASTATIC COLORECTAL CANCER ARE COMMONLY DRIVEN BY SPECIFIC SPECTRUMS OF DEFECTIVE DNA MISMATCH REPAIR COMPONENTS.

Authors:  John M Carethers
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

Review 5.  DNA testing and molecular screening for colon cancer.

Authors:  John M Carethers
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-17       Impact factor: 11.382

6.  Microsatellite Instability Pathway and EMAST in Colorectal Cancer.

Authors:  John M Carethers
Journal:  Curr Colorectal Cancer Rep       Date:  2017-02-02

Review 7.  Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.

Authors:  John M Carethers; Barbara H Jung
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

Review 8.  Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.

Authors:  John M Carethers; Elena M Stoffel
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

9.  Biomarker-directed Targeted Therapy in Colorectal Cancer.

Authors:  John M Carethers
Journal:  J Dig Cancer Rep       Date:  2015-06

10.  Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity.

Authors:  Moriya Iwaizumi; Stephanie Tseng-Rogenski; John M Carethers
Journal:  Mutat Res       Date:  2013-04-30       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.